<DOC>
	<DOC>NCT01393093</DOC>
	<brief_summary>The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).</brief_summary>
	<brief_title>Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas</brief_title>
	<detailed_description>This is a prospective, multicentre, random, controlled clinical trial of Transcatheter Arterial Chemoembolization (TACE)with KMG Microsphere Treating Advance-stage Hepatocellular Carinomas.</detailed_description>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>1. Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas 2. clinical stage（The Barcelona Liver Clinic staging system,BCLC B and C)，or can not receive surgical intervention 3. liver function:ChildPugh A、B 4. PST 0—1（Eastern Cooperative Oncology Group Performance Score ,ECOG） 5. Lifespan≥6 months 6. First time to receive treatment 7. Can accept the follow up 8. informed consent was gotten 9. the number of lesion ≤ 5 1. pregnant or lactation woman 2. emotional disturbance 3. serious heart ,lung disfunction or serious diabetes mellitus 4. serious reactiveness infections;（exp:type B or C hepatitis） 5. liver function :ChildPugh Score C 6. thrombocyte＜6×109/L 7. diffuse HCC 8. widespread metastasis 9. serious atherosclerosis 10. acquired immunodeficiency syndrome;AIDS 11. thrombosis or thrombosis event in 6 months 12. renal inadequacy who need hemodialysis or peritoneal dialysis 13. with other tumors except basal cell carcinoma and carcinoma in situ of cervix 14. serious alimentary tract hemorrhage in 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>HCC</keyword>
	<keyword>TACE</keyword>
</DOC>